STING1 and cancer: Finally, while we leveraged a poly(DMA) carrierand cathepsin B-cleavable linker, the synthetic workflow employedallows for future exploration of SAPCons comprising different polymerbackbones, polymer architectures, and drug linker chemistries to improvethe efficacy and/or safety of systemically administered STING agonistsfor cancer immunotherapy.